Abstract: Ferrostatin-1 (Fer-1) is a potent, synthetic lipophilic antioxidant and a specific inhibitor of ferroptosis, a form of iron-dependent programmed cell death characterized by excessive lipid peroxidation. In the field of cardiology, the dysregulation of iron metabolism and the induction of ferroptosis have been increasingly recognized as pivotal mechanisms underlying various cardiovascular diseases (CVDs). This review summarizes the pharmacological activity, molecular mechanisms, and structure-activity relationships of Fer-1 in cardiovascular contexts based on current literature. Preclinical evidence demonstrates that Fer-1 effectively mitigates cardiac impairments, pathological remodeling, and fibrosis in conditions such as atherosclerosis, hypertension, pulmonary hypertension, and various forms of cardiomyopathy (including sepsis- and doxorubicin-induced). Despite its promising therapeutic potential, the clinical translation of first-generation Fer-1 is currently limited by its pharmacokinetic properties, prompting the development of next-generation analogs. Future perspectives highlight the necessity of optimizing Fer-1 derivatives and conducting clinical trials to establish ferroptosis inhibition as a viable therapeutic strategy for cardiovascular diseases.
1. Introduction
Ferroptosis is a recently identified, iron-dependent form of regulated cell death driven by intracellular iron accumulation and excessive lipid peroxidation [1]. It is biochemically distinct from apoptosis and necrosis, and is primarily characterized by the depletion of glutathione (GSH) and the suppression of glutathione peroxidase 4 (GPX4) [1]. In recent years, the dysregulation of iron metabolism and the induction of ferroptosis have been heavily implicated in the pathogenesis of numerous cardiovascular diseases (CVDs), including heart failure, atherosclerosis, hypertension, pulmonary hypertension, and myocardial ischemia/reperfusion (I/R) injury [1][2].
Ferrostatin-1 (Fer-1) is a synthetic, lipophilic antioxidant that was discovered through high-throughput screening as a highly specific and potent inhibitor of ferroptosis [4]. By acting as a radical-trapping antioxidant (RTA), Fer-1 prevents the accumulation of toxic lipid reactive oxygen species (ROS) [3][4]. Given the central role of ferroptosis in cardiovascular pathology, Fer-1 has emerged as a critical pharmacological tool and a promising lead compound for developing novel cardioprotective therapies [1].
2. Pharmacological Activity
In cardiovascular research, Fer-1 has demonstrated significant protective effects across multiple preclinical models of CVDs:
Atherosclerosis: Fer-1 administration in high-fat diet-induced ApoE-/- mice significantly alleviated atherosclerotic lesions. It achieved this by reducing iron accumulation, upregulating SLC7A11 and GPX4, and inhibiting endothelial lipid peroxidation [1].
Hypertension: In angiotensin II (Ang II)-infused hypertensive mice, Fer-1 mitigated myocardial hypertrophy, fibrosis, and pathological cardiac remodeling. It also lowered systolic blood pressure and alleviated hypertensive renal injury by potentiating GPX4 signaling and reducing malondialdehyde (MDA) levels [1].
Pulmonary Hypertension (PH): In monocrotaline-induced PH rat models, Fer-1 improved right ventricular function and reduced vascular remodeling. This was associated with decreased iron content and the suppression of inflammatory pathways, including TLR4, HMGB1, and the NLRP3 inflammasome [1].
Cardiomyopathy and Heart Failure: Fer-1 has shown efficacy in both sepsis-induced cardiomyopathy (SIC) and doxorubicin-induced cardiomyopathy (DIC). In lipopolysaccharide (LPS)-induced SIC, Fer-1 improved cardiac function by downregulating iron content, restoring GPX4 levels, and reducing prostaglandin endoperoxide synthase 2 (PTGS2) and inflammatory cell infiltration [1]. Similarly, in DIC, Fer-1 rescued myocardial hypertrophy and cardiac injury by blocking lipid peroxidation and PTGS2 elevation [1]. Furthermore, ferroptosis inhibition by Fer-1 is considered a key strategy for preventing the progression of heart failure associated with iron overload [2].
3. Molecular Mechanism of Action
The primary molecular mechanism of Fer-1 lies in its function as a lipophilic radical-trapping antioxidant (RTA) within lipid bilayers [3][4].
Lipid ROS Scavenging: Fer-1 directly scavenges lipid alkoxyl and peroxyl radicals, thereby halting the chain reaction of lipid peroxidation that destroys membrane integrity during ferroptosis [4].
Modulation of the System Xc-/GSH/GPX4 Axis: While Fer-1 does not directly synthesize GSH, its administration in cardiovascular models has been shown to upregulate the expression of SLC7A11 (a component of System Xc-) and restore or potentiate the activity of GPX4, the master regulator of ferroptosis [1].
Reduction of Intracellular Iron and Inflammation: Fer-1 treatment effectively reduces intracellular iron accumulation and downregulates PTGS2, a recognized marker of ferroptosis [1]. Additionally, it exerts anti-inflammatory effects by suppressing the TLR4/NF-κB signaling pathway, downregulating high mobility group box-1 (HMGB1), and inhibiting NLRP3 inflammasome activation in cardiovascular tissues [1].
4. Structure-Activity Relationship (SAR)
Fer-1 is an aromatic amine (specifically a diarylamine derivative) [4]. Its anti-ferroptotic efficacy is strictly dependent on its RTA activity within lipid bilayers.
Essential RTA Moiety: The diarylamine structure is crucial for donating a hydrogen atom to lipid peroxyl radicals, neutralizing them. Structural analogs of Fer-1 that lack this RTA activity are completely ineffective at preventing ferroptosis [4].
Lipophilicity: The lipophilic nature of Fer-1 allows it to anchor into cell membranes and mitochondrial membranes, where lipid peroxidation predominantly occurs [3].
Generational Improvements: First-generation Fer-1 possesses inherent pharmacokinetic limitations, such as poor plasma and metabolic stability. This led to the development of second-generation (e.g., SRS 11-92) and third-generation (e.g., SRS 16-86) ferrostatins, which retain the core RTA pharmacophore but feature structural modifications that significantly increase their stability and in vivo tissue protection capabilities [3].
5. Current Limitations
Despite its robust efficacy in preclinical models, the clinical application of Fer-1 faces several limitations:
Pharmacokinetic Shortcomings: The first-generation Fer-1 molecule exhibits poor metabolic and plasma stability, limiting its utility as a systemic therapeutic agent in humans [3].
Lack of Clinical Data: Currently, the evidence supporting Fer-1 in cardiology is derived exclusively from in vitro cellular assays and in vivo animal models (e.g., mice and rats). The safety, optimal dosing, and long-term efficacy of Fer-1 or its analogs in human patients with cardiovascular diseases remain unverified [1].
Complexity of Iron Metabolism: Cardiovascular diseases often involve a complex interplay of functional iron deficiency and iron overload (e.g., in heart failure) [2]. Systemically inhibiting ferroptosis without addressing the underlying systemic iron dyshomeostasis may yield unpredictable off-target effects.
6. Future Perspectives
The identification of ferroptosis as a pathogenic driver in CVDs positions Fer-1 as a vital tool for future cardiovascular pharmacology.
Drug Development: Fer-1 serves as a foundational lead compound. Future medicinal chemistry efforts should focus on optimizing diarylamine RTAs to produce next-generation ferroptosis inhibitors with superior bioavailability, longer half-lives, and targeted delivery to cardiovascular tissues [3][4].
Combination Therapies: Combining Fer-1 derivatives with standard cardiovascular treatments, iron chelators (like deferoxamine), or natural antioxidant compounds could offer synergistic cardioprotection against ischemia/reperfusion injury and heart failure [1][2].
Clinical Translation: Rigorous clinical trials are essential to validate the therapeutic potential of ferroptosis inhibitors in humans, potentially revolutionizing the management of refractory heart failure, atherosclerosis, and drug-induced cardiomyopathies [1].
